


Semintra[®]

For cats with **CKD** and **HT**



Semintra
THE SOLUTION

*CKD = chronic kidney disease
HT = hypertension*

 **Boehringer
Ingelheim**

Hypertension is commonly associated with CKD

Hypertension

Up to 65% of cats with CKD have hypertension¹

65%

CKD

Semintra
THE SOLUTION




Diagnosing cats with CKD in your practice




Renal blood tests

A substantial proportion of cats with CKD are going undetected and untreated


THE PROGRESSION OF CKD IN CATS



Use SDMA to identify CKD as early as 25% loss




The role of SDMA in your practice



Enables diagnosis of CKD
up to 1.5 years earlier²
before symptoms appear

The role of SDMA in your practice



Enables identification of
up to 2.5 x more cats
with CKD³


Semintra
THE SOLUTION

Feline hypertension

- Hypertension is common in older cats⁴
- Early diagnosis is important to avoid target organ damage
- Identifying cats can be challenging


Risk category	Systolic blood pressure (mmHg)	Risk of target organ damage
Normotensive	<140	Minimal
Prehypertensive	140-159	Low
Hypertensive	160-179	Moderate
Severely hypertensive	>180	High

Adapted from Acierno et al (2018)⁵




Idiopathic vs. secondary hypertension

in cats with hypertension⁴



13%
are idiopathic



87%
have CKD,
hyperthyroidism,
or both

Feline hypertension is usually secondary, meaning it is associated with another disease. CKD is the most common condition associated with feline hypertension, followed by hyperthyroidism. Idiopathic hypertension, where there is no apparent underlying disease, is far less common in cats.^{5,6}

Assessing BP in your practice



Semintra
THE SOLUTION

BP = blood pressure

Feline HT – Which cats to screen?

Cats are at risk of hypertension if they:




Have evidence of target organ damage (TOD)

OR



Have a disease associated with hypertension, e.g. CKD or hyperthyroidism


OR



Are aged 9 years or older

- 92% of cats with CKD are 9 years or older⁷
- 98% of cats with hyperthyroidism are 9 years or older⁸
- 24% of all cats 9 years or older have hypertension⁹

How and when to treat cats with HT*



Cats are at risk of hypertension if they:




Have evidence of target organ damage (TOD)

OR



Have a disease associated with hypertension, e.g. CKD or hyperthyroidism

OR




Are aged 9 years or older

*Based on ACVIM guidelines (Acierno, M.J. et al. [2018] ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med 32, 1–20)

Objectives of management


CKD management

The three key strategies for managing progression of CKD



Blood pressure management

The aim of treatment is to reduce systolic blood pressure to within the target range.^{5,10}



Routinely monitor blood pressure to identify cats at risk of target organ damage


Semintra® 4mg/ml

- Licensed for reduction of proteinuria associated with CKD in cats
- Once daily, oral liquid
- 30ml & 100ml




Semintra
THE SOLUTION

Why is renoprotection important?¹¹⁻¹⁷




Semintra® in CKD

Semintra®



Renoprotection¹¹⁻¹⁷



Semintra
THE SOLUTION

Semintra® 10mg/ml

- Licensed for treatment of systemic hypertension in cats
- Once daily, oral liquid
- Initial dose 2mg/kg
- ml syringe allows for dose to be reduced if cat is well controlled**
- In cats with hypertension associated with chronic kidney disease the recommended **minimum** effective dose is 1 mg/kg




Semintra
THE SOLUTION

** when SBP < 140 mmHg the dose can be reduced in 0.5 mg/kg increments, at the vet's discretion

Semintra® in HT

Antihypertensive effect proven in large multicentre clinical trials^{20,21}



Semintra® provided a significant reduction in blood pressure on day 14 compared to placebo ($p < 0.0001$)

Take the pressure off with our support



Register now at:
www.boehringer-academy.co.uk

For vets

For owners



Technical Services Team contact details

01344 746957 (UK) or 01 291 3985 (IE)

vetenquiries@boehringer-ingelheim.com

9-5 (Mon-Thu), 9-4.30 (Fri)

24/7 365 emergency advice service*

*If you have an emergency outside office hours, just call one of the numbers above and follow the instructions.

References

1. Stiles J, et al. J Am Anim Hosp Assoc. 1994;30:564-572.
2. Hall, JA. et al. J Vet Intern Med. 2014;28:1676-1683.
3. Data on file at IDEXX Laboratories, Westbrook, Maine, US.
4. Jepson RE, et al. J Vet Intern Med. 2007;21(3):402-409.
5. Acierno MJ, et al. J Vet Intern Med. 2018;1-20.
6. Taylor S, et al. J Feline Med Surg. 2017;19(3):288-303.
7. Conroy, M. et al. (2019) Chronic kidney disease in cats attending primary care practice in the UK: a VetCompass™ study. Vet Rec. 184(17), 526.
8. Stephens, M.J. et al. (2014) Feline hyperthyroidism reported in primary-care veterinary practices in England: prevalence, associated factors and spatial distribution. Vet Rec. 175(18), 458.
9. Conroy, M. et al. (2018) Survival after diagnosis of hypertension in cats attending primary care practice in the United Kingdom. J Vet Intern Med. 32(6), 1846-1855.
10. Summary of Product Characteristics (SPC): Semintra®(telmisartan). European Medicines Agency.
11. Reynolds, BS. Et Lefebvre, HP. J Feline Med Surg. 2013,15(1 suppl):3-14.
12. Dinh, DT. et al. Clin Sci (Lond). 2001; 100:481-492.
13. European Public Assessment Report (EPAR): Semintra® (telmisartan). London: European Medicines Agency, 2013. Available at www.ema.europa.eu.
14. Ruggenenti, P. et al. J Am Soc Nephrol. 2001; 12:2832-2837.
15. Roscioni, SS. et al. Kidney International. 2014; 86:40-49.
16. Taylor, S. Et Sparkes, A. J Feline Med Surg. 2013; 15(1 suppl):45-52.
17. Syme, HM. et al. J Vet Intern Med. 2006; 20:528-535.
18. Sent U, et al. J Vet Intern Med. 2015 Nov-Dec;29(6):1479-1487.
19. Volpe M, et al. J Am Soc Nephrol. 2002;13 Suppl 3:S173-178.
20. Glaus, TM, et al. Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial. J Vet Intern Med. 2019; 33: 413- 422.
21. Coleman AE, et al. Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial. J Vet Intern Med. 2019;33(2):478-488.

Semintra® contains telmisartan. Semintra® 4 mg/ml oral solution for cats and Semintra® 10 mg/ml oral solution for cats are indicated for the reduction of proteinuria associated with chronic kidney disease (CKD) in cats and for the treatment of systemic hypertension in cats. IE: POM. For information about side effects, precautions, warnings and contraindications please refer to the product packaging and package leaflet. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. IE Tel: 01 291 3985 (all queries). Email: vetenquiries@boehringer-ingelheim.com. Semintra® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. Copyright 2023 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Jun 2023. UI-FEL-0054-2023. Use Medicines Responsibly.